Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Tenalisib (RP6530, selective dual PI3K d/γ inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial in patients with locally advanced or metastatic HR+/HER2...
Product Name : RP6530
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : RP7214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) inhibitor with reduced nanomolar potency, in Covid-19 patients with mild, symptomatic disease.
Product Name : RP7214
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2021
Lead Product(s) : RP7214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies.
Product Name : RP6530
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP12146
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rhizen indicated that RP12146 has comparable preclinical activity vis-à-vis approved PARP inhibitors and shows improved preclinical safety that it expects will translate in the clinic.
Product Name : RP12146
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : RP12146
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.
Product Name : RP6530
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Tenalisib,Romidepsin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rhizen Presents Tenalisib + Romidepsin Phase I/II Data in R/R T-cell Lymphoma
Details : RP6530 (tenalisib) is a highly selective next generation orally active dual PI3K δ/γ inhibitor being investigated with Romidepsin for relapsed/refractory T-Cell lymphoma.
Product Name : RP6530
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Tenalisib,Romidepsin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous T-cell Lymphoma patients (PTCL and CTCL).
Product Name : RP6530
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable